A Phase IIa Randomized Double-blind Placebo-controlled Two-way Cross-over Trial of the Effects of Repeat Doses of 50 mg AXP1275 Daily on the Asthmatic Response to a Pulmonary Allergen Challenge in Adults With Mild-to-Moderate Atopic Asthma
Phase of Trial: Phase II
Latest Information Update: 20 May 2015
At a glance
- Drugs AXP 1275 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 27 Aug 2014 Planned number of patients changed from 20 to 21 as reported by ClinicalTrials.gov record..
- 27 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Jul 2013 New trial record